To the editor: We read with interest the recent article by Hoster and colleagues from the German Low Grade Lymphoma Study Group (GLSG) and the European Mantle Cell Lymphoma Network regarding a new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.[1][1] The MIPI was
No takes yet. Share an insight, caveat, or question.
Shah et al. (2008) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: